Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 147
- Registration Number
- NCT02924376
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 59
- Registration Number
- NCT02917993
- Locations
- 🇺🇸
Valley Hospital, 223 N Van Dien Avenue, Ridgewood, New Jersey, United States
🇺🇸West Virginia University Cancer Institute, 1 Medical Center Drive, Morgantown, West Virginia, United States
🇺🇸University of Texas -MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, United States
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
- Conditions
- Lung CancerRenal Cell Carcinoma (RCC)MesotheliomaMetastatic CancerSolid TumorsColorectal Cancer (CRC)Bladder CancerUC (Urothelial Cancer)Gastric CancerHead and Neck Cancer
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 260
- Registration Number
- NCT02903914
- Locations
- 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸BIDMC, Boston, Massachusetts, United States
🇺🇸MD Anderson, Houston, Texas, United States
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 263
- Registration Number
- NCT02872714
- Locations
- 🇩🇪
Klinikum Dresden Standort Dresden-Friedrichstadt, Dresden, Germany
🇩🇪Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany
🇩🇪Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 450
- Registration Number
- NCT02763319
- Locations
- 🇬🇧
MorphoSys Research Site, Southend on Sea, United Kingdom
🇬🇧Morphosys Research Site, Birmingham, United Kingdom
🇨🇿Morphosys Research site, Olomouc, Czechia
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 33
- Registration Number
- NCT02760485
- Locations
- 🇺🇸
LAC-USC Medical Center/Kenneth Norris Jr Cancer Hospital, Los Angeles, California, United States
🇺🇸Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 706
- Registration Number
- NCT02752074
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 171
- Registration Number
- NCT02723994
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Texas Childrens Hospital, Houston, Texas, United States
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
- Conditions
- MPN (Myeloproliferative Neoplasms)
- Interventions
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 74
- Registration Number
- NCT02718300
- Locations
- 🇺🇸
California Cancer Associates For Research and Excellence, Fresno, California, United States
🇺🇸Baylor Scott and White Research Institute, Dallas, Texas, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
- Conditions
- Solid Tumors and Hematologic Malignancy
- Interventions
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 116
- Registration Number
- NCT02712905
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Kansas Center for Research, Inc., Kansas City, Kansas, United States